论文部分内容阅读
研究背景:微量白蛋白尿(MA)是糖尿病肾病最早的临床表现,是心血管疾病和死亡率增高的重要标志。早期检测能使个体化的积极治疗及早实施,合并高血压又增加了心血管死亡的危险因素。MAPS是第一个在亚洲有关2型糖尿病合并高血压的高危人群中微量白蛋白尿患病率的研究。
Research Background: Microalbuminuria (MA) is the earliest clinical manifestations of diabetic nephropathy, an important marker of cardiovascular disease and increased mortality. Early detection can enable aggressive individualized treatment as soon as possible, combined with hypertension and increased risk of cardiovascular death. MAPS is the first in Asia to study the prevalence of microalbuminuria in high-risk populations with type 2 diabetes and hypertension.